Nucleolar Sequestration: Visitors to the Nucleolus {#s1}
==================================================

The role of the nucleolus as the site of ribosome biosynthesis has been established since the mid-1960s ([@B102]; [@B103]; [@B87]). Nucleoli are built around tandem repeats of ribosomal DNA (rDNA) in nucleolar organizing regions (NORs) and structurally dependent on active transcription of rDNA ([@B48]; [@B109]). Each nucleolus consists of a tripartite organization which is classically defined by their different appearances under electron microscopy (EM) ([@B101]): the fibrillar center (FC), where the RNA polymerase I machinery is active; the dense fibrillar component (DFC) that is enriched in fibrillarin (FIB1); and the granular component (GC) that harbors B23. RNA polymerase I activity is believed to occur at the interface between the FC and the DFC, while processing of newly synthesized ribosomal RNA (rRNA) and assembly with ribosomal proteins occur within the GC ([@B117]; [@B130]). The traditional role of the nucleolus as a hub of rRNA synthesis and ribosome assembly has been the subject of many excellent literature surveys ([@B17]; [@B101]; [@B94]). This review focuses on a lesser known phenomenon originally coined "nucleolar sequestration," which describes the ability of the nucleolus to sequester regulatory proteins in response to cellular cues ([@B35]; [@B100]; [@B21]).

2019 marks 20 years since nucleolar sequestration was first hypothesized ([@B12]) following the discoveries that cell cycle regulator Cdc14 phosphatase and E3 ubiquitin ligase MDM2 could be temporarily localized in nucleoli to affect cell cycle progression ([@B123]; [@B133]; [@B138]; [@B71]; [@B16]). In *Saccharomyces cerevisiae*, Cdc14 is sequestered in the nucleolus by Cfi1/Net1 until anaphase onset when it is released to promote exit from mitosis ([@B123]; [@B133]). In mammalian cells, nucleolar sequestration of MDM2 prevents it from binding and exporting p53 into the cytoplasm for degradation ([@B138]; [@B71]; [@B16]). This stabilizes p53 in the nucleus, where it acts as a transcription factor that promotes growth arrest or apoptosis. The E3 ubiquitin ligase von Hippel--Lindau protein (VHL) is another example of nucleolar sequestration ([@B82]). VHL promotes the degradation of the transcription factor hypoxia-inducible factor (HIF) under normal oxygen conditions. Low extracellular pH triggers nucleolar sequestration of VHL, enabling HIF to evade degradation and promote transcription of target genes involved in oxygen homeostasis. [**Table 1**](#T1){ref-type="table"} summarizes the reports of nucleolar sequestration that have been observed for many other proteins under various cellular conditions. Taken together, these underscore a fundamental cellular strategy that uses the nucleolus to regulate protein dynamics in response to cellular cues.

###### 

List of the proteins whose activities have been reported to be regulated by nucleolar sequestration.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protein symbol   Full name                                          Stimulus                                    Nucleolar response   Model system        Reference
  ---------------- -------------------------------------------------- ------------------------------------------- -------------------- ------------------- ------------
  Cdc14            Cell division cycle 14                             Anaphase                                    Release              *S. cerevisiae*     ([@B123])\
                                                                                                                                                           ([@B133])

  Pch2             Pachytene checkpoint 2                             Meiotic prophase arrest                     Release              *S. cerevisiae*     ([@B113])

  MDM2             Murine double minute 2 homolog                     Ribosomal stress\                           Capture              Mammalian           ([@B138])\
                                                                      DNA damage                                                                           ([@B71])\
                                                                                                                                                           ([@B16])

  hTERT            Human telomerase reverse transcriptase             Transformation, DNA damage\                 Release\             Mammalian           ([@B142])
                                                                      Ionizing radiation                          Capture                                  

  c-Myc            Proto-oncogene c-Myc                               Proteasomal stress                          Capture              Mammalian           ([@B4])

  ADAR2            Adenosine deaminase that acts on RNA 2             Inhibition of rRNA synthesis                Release              Mammalian           ([@B112])

  VHL              von Hippel Lindau tumor suppressor                 Extracellular acidosis                      Capture              Mammalian           ([@B82])

  RelA             p65 subunit of transcription factor\               Aspirin, serum withdrawal, UV-C radiation   Capture              Mammalian           ([@B126])\
                   NF-κB                                                                                                                                   ([@B26])

  Polycomb         Polycomb                                           Cell differentiation                        Capture              *D. melanogaster*   ([@B27])

  Hand1            Heart and neural crest derivatives expressed 1     Cell differentiation                        Capture/Release      Mammalian           ([@B76])

  Hsc70            Heat shock chaperone 70                            Recovery from heat shock                    Capture              Mammalian           ([@B14])

  Ulp1             Small ubiquitin-related modifier (SUMO) protease   Alcohol                                     Capture              *S. cerevisiae*     ([@B127])

  p53              Cell cycle regulator; tumor suppressor             Proteasomal inhibition (MG132)              Capture              Mammalian           ([@B61])\
                                                                                                                                                           ([@B64])

  Piwi             piRNA binding protein                              Heat shock                                  Capture              *D. melanogaster*   ([@B86])
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Nucleolar Sequestration: A Case of Protein Immobilization {#s2}
=========================================================

The Nucleolar Detention Centers {#s2_1}
-------------------------------

Pioneering work by [@B105] showed that proteins are highly mobile and rapidly exchange between affinity interactions and the cellular milieu. The nucleolus is considered a dynamic droplet, assembled by demixing of its three sub-structural liquid phases (i.e., FC, DFC, and GC), which are composed of highly mobile proteins ([@B23]; [@B38]; [@B52]; [@B116]). It is remarkable, then, that proteins undergoing nucleolar sequestration are non-dynamic or immobile ([@B82]; [@B83]; [@B6]; [@B55]). This has been demonstrated for Cdc14 ([@B131]), MDM2 ([@B6]), VHL ([@B83]), RNF8 ([@B85]), DNMT1 ([@B6]), and Piwi ([@B86]), amongst other proteins. Even resident nucleolar proteins such as RNA polymerase I subunit RPA16, Pescadillo, and SENP3 can undergo cycles of mobility/immobility ([@B55]). For example, VHL switches from a highly dynamic, uniform distribution under standard growth conditions (21% O~2~, pH 7.4) to an immobilized state in the nucleolus on exposure to extracellular acidosis (1% O~2~, pH 6.0) ([@B83]). Only upon neutralization of extracellular pH is VHL released from the nucleolus to return to its original distribution and mobility ([@B83]). These nuclear foci that contain sequestered/immobile proteins were originally called "nucleolar detention centers," as targets are both localized and detained within the nucleolus, unable to freely diffuse elsewhere ([@B83]; [@B7]; [@B55]). From this perspective, the function of nucleolar detention or immobilization is to temporarily inactivate relevant proteins, inhibiting their access to downstream effectors. Just as possible, though, is that the clustering of detained proteins may render an enzymatic reaction more efficient. For example, immobilized nucleolar Cdc14 maintains Spo12 dephosphorylation to regulate cell cycle progression ([@B131]). In addition, Piwi switches from its canonical role as a non-nucleolar transposable element repressor to a rDNA-specific repressor when it is sequestered in the nucleolus ([@B86]). From these studies, it is clear that cells have evolved a strategy to regulate molecular networks by reversibly switching proteins between a mobile and an immobile state. Whether nucleolar sequestration represents a loss- or gain-of-function might depend on the proteins undergoing immobilization.

Mechanisms of Nucleolar Sequestration {#s2_2}
-------------------------------------

The ability of the nucleolus to sequester a wide variety of proteins in various cellular contexts suggests multiple mechanisms for nucleolar sequestration. Pathway analysis of interactions between resident nucleolar proteins and visitor proteins indicates that sequestered proteins interact either directly or indirectly, with the same small subset of "hub" nucleolar proteins, which primarily includes B23/NPM and Nucleolin ([@B35]). Nucleolar retention of highly dynamic proteins through interactions with less mobile "hub" nucleolar partner(s) anchored by multivalent protein and RNA interactions contribute to nucleolar plasticity ([@B88]). Cdc14 is anchored in the nucleolus for most of the cell cycle through its association with Cfi1/Net1 ([@B123]; [@B133]). During anaphase onset, a signaling cascade of phosphorylation inhibits the interaction of Cdc14 with Net1, releasing it to act as a mitotic exit activator ([@B11]). ARF binding to MDM2 unmasks a cryptic nucleolar localization signal (NoLS) within its C-terminal RING domain, which is essential for MDM2 nucleolar sequestration ([@B129]; [@B138]; [@B71]; [@B139]). During DNA damage and acidosis, MDM2 is shuttled into the nucleolus by direct binding to PML (promyelocytic leukemia protein) ([@B16]), itself a target of nucleolar sequestration ([@B78]). MDM2 can also be sequestered in nucleoli by binding to ATP, independently of ARF ([@B107]). Alternatively, MDM2 binds ribosomal proteins (e.g., RPL5 and RPL11) that are released into the nucleoplasm during ribosomal stress, which stabilizes p53 ([@B21]; [@B70]). Mapping analysis of VHL identified an approximately 30-amino acid fragment referred to as a nucleolar detention signal (NoDS) that is necessary and sufficient to immobilize proteins in nucleoli ([@B85]). The NoDS is composed of an arginine/histidine-rich sequence followed by two or more hydrophobic LXV motifs where X can be any hydrophobic residue (e.g., LWL, LLV, LFV, and LQV). A survey of proteins containing NoDS identified many candidates harboring this motif, including DNA methyltransferase I DNMT1, PML, and DNA polymerase delta catalytic subunit POLD1, all shown to be immobilized in nucleoli under extracellular acidosis ([@B85]; [@B6]). The NoDS interacts with inducible long noncoding RNA derived from the ribosomal intergenic spacer (rIGSRNA) ([@B6]). Silencing of rIGSRNA is sufficient to prevent both the formation of nucleolar detention centers and immobilization of NoDS-containing proteins ([@B6]). The identification of the NoDS in many proteins provided evidence that nucleolar sequestration is a common cellular strategy to regulate protein function ([@B85]).

Biochemical Properties of Nucleolar Detention Centers {#s3}
=====================================================

Nucleolar Detention Centers Display Amyloidogenic-Like Characteristics {#s3_1}
----------------------------------------------------------------------

In various physiological settings, proteins with limited mobility often display amyloid-like properties ([@B58]; [@B15]). Amyloidogenesis is the process whereby soluble proteins assemble into aggregates known as amyloid fibrils ([@B60]). Because of their association to neurodegenerative disorders, including Alzheimer's and Parkinson's disease, amyloids were classically perceived as exclusively toxic protein aggregates ([@B119]; [@B60]). The discovery of functional amyloid Pmel17 in 2006 challenged the notion that the amyloid state is merely pathological ([@B40]). Since then, several groups have reported the existence of functional/physiological amyloids in different organisms ([@B28]; [@B41]; [@B75]; [@B36]; [@B39]; [@B67]; [@B58]; [@B15]; [@B128]; [@B111]; [@B25]). Nucleolar detention centers composed of proteins such as VHL, MDM2, POLD1, etc., share many properties beyond immobility that are associated with the amyloid state. First, these nuclear foci stained positive with amyloidophilic dyes such as Congo red, Thioflavin S/T, and Amylo-Glo, all of which recognize different biochemical features of amyloids ([@B5]). Second, the nucleolar detention centers stain positive for the OC fibril antibody that specifically targets the amyloid fibril conformation ([@B59]). Third, immobilized proteins found in these nuclear foci displayed biochemical properties associated with amyloids, including resistance to proteinase K, insolubility in common detergents, and can only be dissociated into monomers by SDS/high temperature ([@B5]). Arguably the utmost unique feature of amyloid bodies is their electron-dense fibrillar organization, which would be as predicted for a condensate enriched in amylogenic proteins ([@B55]; [@B5]). Consequently, the terms "nucleolar detention centers" and NoDS were replaced with "amyloid bodies" (A-bodies) and "amyloid-converting motif" (ACM), respectively, to reflect the transformation of the nucleolus into an A-body, a molecular prison of proteins in their amyloid-like state. [**Figure 1A**](#f1){ref-type="fig"} shows an example of this dramatic and reversible transformation of the tripartite nucleolus into the fibrillar A-body in cells responding to stimuli.

![Nucleolar sequestration: the reversible remodeling of the nucleolus into an amyloid body. **(A)** During stimuli (heat shock or extracellular acidosis), the tripartite nucleolus undergoes a dramatic transformation into electron-dense fibrillar organization that characterizes an amyloid body. The fibers contain immobilized proteins in an amyloid-like state. After stimuli termination, an amyloid body is disaggregated and transforms back into the tripartite nucleolus. **(B)** The fibrillar amyloid bodies are distinct from the amorphous, electron-dense nucleolar caps (16 h cisplatin) or the electron-light nucleolar aggresomes (16 h MG132). *FC,* fibrillar component; *DFC*, dense fibrillar component; *GC*, granular component. Scale represents 1 µm. Amyloid body and nucleolar aggresome taken from ([@B8]) and ([@B61]), with permission.](fgene-10-01179-g001){#f1}

Amyloid Bodies Are Distinct From Liquid-Like Biomolecular Condensates and Other Nucleolar Organizations {#s3_2}
-------------------------------------------------------------------------------------------------------

Purification and mass spectrometry analysis have identified hundreds of cellular proteins that are captured in A-bodies, many of which were shown to undergo immobilization by photobleaching experiments ([@B85]; [@B6]; [@B5]). Because A-bodies contain an array of immobilized proteins in an amyloid-like state, we suggested the term "systemic physiological amyloidogenesis" to describe A-body biogenesis, in keeping with the original terminology to describe functional amyloids ([@B28]; [@B41]; [@B75]). Other laboratories have also proposed that A-body formation represents an amyloidogenic liquid-to-solid phase transition ([@B72]; [@B65]; [@B46]) and used the terms "solid," "solid-like," or "non-dynamic" biomolecular condensates to describe this membraneless organelle ([@B72]; [@B140]; [@B25]; [@B51]; [@B143]; [@B53]; [@B37]; [@B65]). Prior to the discovery of A-bodies, the terms "liquid-to-solid phase transition" and "solid" had been reserved to describe the formation of pathological aggregates ([@B99]; [@B92]; [@B56]; [@B77]; [@B104]; [@B106]). Other physiological examples of "solid-like" structures include Balbiani bodies observed in *Xenopus* ([@B18]) and pH-regulated fluid-to-solid transition of the cytoplasm in yeast ([@B91]). The fibrous, amyloid-like characteristic of the A-body differentiates it from other biomolecular condensates that display liquid-like properties ([@B22]; [@B23]; [@B137]; [@B149]; [@B13]; [@B122]), such as stress granules, nucleoli, and paraspeckles, amongst others ([@B50]; [@B42]; [@B62]; [@B110]; [@B31]; [@B132]; [@B98]; [@B115]; [@B19]; [@B73]; [@B101]; [@B108]). Liquid-like biomolecular condensates are dynamic, their constituents are mobile, they do not form fibers detectable by EM nor do they typically stain with amyloidophilic dyes ([@B105]; [@B122]; [@B140]). The biochemical and biophysical differences between dynamic, liquid-like, and non-dynamic or solid-like condensates are summarized within [**Table 2**](#T2){ref-type="table"}.

###### 

Biochemical, biophysical, and dynamic properties of liquid-like condensates or solid-like condensates with amyloid characteristics.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                Liquid-like condensates                                                                      Solid-like condensates
  --------------------------------------------- -------------------------------------------------------------------------------------------- -----------------------------------------------------------------------
  Examples                                      Cytoplasm stress granules ([@B108])\                                                         Amyloid bodies ([@B8])\
                                                P-bodies ([@B98])\                                                                           Balbiani bodies ([@B18])
                                                Nuclear stress granules ([@B110]; [@B132])\                                                  
                                                Cajal bodies ([@B42]; [@B73])\                                                               
                                                Nuclear speckles ([@B62])\                                                                   
                                                Nuclear paraspeckles ([@B19]; [@B115])\                                                      
                                                Nucleoli ([@B101])\                                                                          
                                                PML nuclear bodies ([@B50]; [@B31])                                                          

  Protein mobility                              Proteins are mobile; continuously exchanging with the structure and the surrounding milieu   Proteins are immobile; engaged in strong intermolecular interactions

  Shape                                         Spherical                                                                                    Spherical or fibrous

  Biochemical and biophysical characteristics   • Structure is dynamic; exhibiting properties of water droplets:Fluid\                       • Structure is non-dynamic; exhibiting properties of amyloids:Static\
                                                • Cycles of fusion (coalescence) and fission\                                                • Fibrillar organization\
                                                • Wetting behavior\                                                                          • Positive staining with amyloidophilic dyes (e.g., Congo red)\
                                                • Flows under shear force                                                                    • Resistant to proteinase K\
                                                                                                                                             • Insoluble in common detergents\
                                                                                                                                             • Cross-β diffraction pattern

  Material properties                           Viscous                                                                                      Elastic

  Function                                      Biochemical reactions                                                                        Cell dormancy

  Mechanism                                     Liquid--liquid phase separation                                                              Liquid-to-solid phase transition
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A-bodies may also be contrasted from other stress-induced nucleolar structures, namely, nucleolar caps ([@B121]) and nucleolar aggresomes ([@B64]; [@B64]; [@B65]) ([**Figure 1B**](#f1){ref-type="fig"}). Transcriptional inhibition of Pol I results in nucleolar segregation, in which the FC and GC phases separate, perhaps as a consequence of changes in surface tension ([@B122]) resulting in the formation of perinucleolar caps that surround the segregated nucleolus ([@B121]). Proteasomal inhibition induces nucleolar inclusions called nucleolar aggresomes that contain proteins marked for degradation, and various RNAs ([@B64]). By EM, A-bodies have a unique fibrillar organization characteristic of amyloids, whereas nucleolar caps appear as electron-dense amorphous structures and nucleolar aggresomes are cavernous, occupying a large electron-light central space of the nucleolus ([@B61]) ([**Figure 1B**](#f1){ref-type="fig"}). Interestingly, while the formation of nucleolar caps and A-bodies is accompanied by a redistribution of nucleolar components and subsequent arrest of ribosomal biogenesis ([@B121]; [@B84]; [@B55]), nucleolar aggresomes require transcriptionally active nucleoli to form ([@B64]; [@B64]), with all nucleolar components intact and visible by EM. Additionally, proteins are dynamically sorted into nucleolar caps and remain mobile ([@B121]), while several proteins in A-bodies and nucleolar aggresomes are immobile ([@B83]; [@B6]; [@B55]; [@B5]). Another recently identified nucleolar stress body, nucleolar amyloid bodies (NoABs), is induced by prematurely terminated peptides that diffuse through the nuclear pores and aggregate within the nucleolus ([@B81]). EM has not been reported for NoABs. It remains to be tested if NoABs are rIGSRNA-dependent, as are A-bodies, and if prematurely terminated peptides are involved in nucleolar sequestration of full-length proteins. While there are definitive similarities between the different stress-induced nucleolar organizations and that proteins can undergo sequestration in nucleolar aggresomes (both are discussed in ([@B65]), A-bodies represent a unique nucleolar structure based on their fibrous properties and dependency on rIGSRNA.

Protein Immobilization Into A-Bodies: A Choreographed Multistep Pathway {#s4}
=======================================================================

How membraneless subcellular condensates maintain their unique identities and how proteins and/or RNA are sorted into these condensates remain subjects of active research. New insights into the biophysical properties of biomolecular condensates have demonstrated unexpected links between the sequence-encoded information in protein and RNA components of compartments and the material properties they impart ([@B57]; [@B3]; [@B24]; [@B34]; [@B89]; [@B96]; [@B97]; [@B122]; [@B140]; [@B63]). Recent studies demonstrated the importance of RNA-binding proteins with prion-like, low-complexity domains in forming biomolecular condensates. Equally as exciting has been the work done to uncover the specific sequences or structural elements embedded in architectural RNA that dictate the biophysical properties of biomolecular condensates ([@B29]; [@B30]; [@B144]; [@B49]). With these new tools, we have begun to understand how specific elements within RNA and proteins are involved in condensate biogenesis.

A Working Model of A-Body Biogenesis {#s4_1}
------------------------------------

[**Figure 2**](#f2){ref-type="fig"} proposes a stepwise working model of A-body biogenesis that integrates different opinions in the literature, showcasing this process as a precisely choreographed multistep routine rather than simply a random aggregation of misfolded proteins. The first step in the formation of A-bodies is the appearance of several transient foci that are distinct from known nucleolar layers ([@B136]). These foci are spherical, contain mobile proteins, and can undergo fusion, thereby displaying some of the properties associated with dynamic condensates. An interesting feature of the inducible nucleolar foci is that they stain positive for 1-anilino-8-naphthalenesulfonate (ANS), a dye specific for hydrophobic regions of proteins and used *in vitro* to detect the molten globule state, a precursor of amyloid fibrils ([@B20]). EM revealed that ANS-positive foci correspond to electron-dense, amorphous aggregates concomitant with loss of the typical tripartite organization of transcriptionally active nucleoli. In the second step, the stimulus-induced foci rapidly mature into Congo red-positive aggregates that contain immobilized proteins, limiting their ability to diffuse within the nucleolus. We coined these maturing foci "nascent A-bodies." Photobleaching analysis showed that, once formed, nascent A-bodies expand by directly capturing and immobilizing free proteins (step 3) ([@B136]). Maturation of A-bodies terminates once the pools of cellular mobile proteins have been depleted, culminating in a distinct fibrous organization. Disassembly of A-bodies occurs within 1--2 h after stimulus termination, a process that requires heat shock proteins hsp70 and hsp90 (step 4) ([@B5]).

![Working model: amyloid body biogenesis is a precisely choreographed routine. We propose that, on stimulus, low-complexity ribosomal intergenic spacer RNA (rIGSRNA) derived from the rDNA intergenic spacer accumulate in the nucleolus. Step 1: Low-complexity rIGSRNA interact with short cationic peptides, such as the R/H-rich sequence of the ACM (formally NoDS), to form nucleolar liquid-like foci. Step 2: Local concentration of proteins with amyloidogenic propensity in the foci triggers physiological amyloidogenesis and generates nascent amyloid bodies (A-bodies). Step 3: Once seeded, nascent A-bodies self-assemble into fibrillar, solid-like A-bodies. A-bodies enable cells to rapidly and reversibly store a large array of proteins and enter cellular dormancy in response to stress. Step 4: Upon recovery/stimulus termination, A-body disaggregation is mediated by heat shock protein (hsp) chaperones 70 and 90. Through these steps, A-body biogenesis may represent a physiological liquid-to-solid phase transition.](fgene-10-01179-g002){#f2}

Low-Complexity rIGSRNA Drive Formation of Inducible Nucleolar Foci {#s4_2}
------------------------------------------------------------------

In mammals, the nucleolus is organized around a scaffold of ∼400 rDNA tandem repeats of 43 kb, of which approximately half are transcriptionally active ([@B94]; [@B120]). Each repeat consists of an rDNA enhancer/promoter located directly upstream of rRNA genes separated by a ribosomal intergenic spacer (rIGS) of variable length and organization ([@B44]; [@B125]) ([**Figure 3A**](#f3){ref-type="fig"}). The rIGS is an enigmatic region of the human genome historically, and erroneously, called the "non-transcribed region" ([@B125]). Interestingly, in recent years, species conservation ([@B1]) and functional studies have demonstrated that these regions of the genome are transcriptionally active, generating various non-coding RNA (ncRNA) ([@B54]; [@B9]). These ncRNA from the rIGS are involved in regulating rRNA expression ([@B80]; [@B79]; [@B118]; [@B146]; [@B147]; [@B148]) and thereby responsible for maintaining a significant fraction of the rDNA cassettes in a heterochromatic, transcriptionally silent chromatin structure ([@B45]; [@B114]), controlling PTBP1-regulated alternative splicing ([@B145]), and assembling A-bodies ([@B6]; [@B55]; [@B5]; [@B136]) ([**Figure 3A**](#f3){ref-type="fig"}). The various rIGS ncRNA appear to be products of RNA polymerase I ([@B80]; [@B6]), except for the antisense PAPAS, which is transcribed by RNA polymerase II ([@B146]).

![Induction of non-coding RNA (ncRNA) from the ribosomal cassette. **(A)** Schematic of a single human rDNA repeat unit, which is composed of a ∼13-kb pre-rRNA coding region flanked by a ∼30-kb intergenic spacer (rIGS). The rIGS transcribes several functional non-coding RNA. Stimuli-specific loci of rIGS produce ribosomal intergenic spacer RNA (rIGSRNA) required for A-body formation. rIGS~28~RNA and rIGS~16~RNA/rIGS~22~RNA are produced under acidotic (*yellow*) and heat shock (*red*) conditions, respectively. No function has been ascribed to rIGS~18~RNA yet. Other ncRNA found in the rIGS include a \>10-kb transcript called PNCTR (pyrimidine-rich non-coding transcript) involved in PTBP1 binding (purple), *pRNA* (green), and antisense PAPAS (brown) involved in rRNA regulation, as well as Alu element-derived (gray boxes) RNA involved in nucleolar architecture. **(B)** rIGSRNA contain low-complexity sequences comprising of long dinucleotide repeats, as determined by RNA sequencing, RT cloning, and RNA-FISH. This is in contrast to other ncRNA that display high complexity, i.e., possess secondary structure, such as pRNA.](fgene-10-01179-g003){#f3}

The appearance of nucleolar foci under stress coincides with the induction of rIGS~28~RNA in acidosis, and rIGS~16~RNA and rIGS~22~RNA in heat shock ([**Figure 3**](#f3){ref-type="fig"}). Recent work suggests that low-complexity dinucleotide repetitive sequences operate as the architectural determinants of rIGSRNA to recruit proteins to A-bodies ([@B136]) ([**Figure 3B**](#f3){ref-type="fig"}). Live cell imaging and *in vitro* assays indicated that positively charged R/H-rich peptide domains of the ACM ([**Figure 4**](#f4){ref-type="fig"}) co-assemble more efficiently with the negatively charged low-complexity sequences of rIGSRNA than with flanking high-complexity RNA sequences to form the inducible nucleolar foci ([@B136]). The rIGSRNA/ACM interactions *in vitro* and *in vivo* are particularly sensitive to even the slightest increase in salt concentration. This contrasts other phase-separated compartments of the nucleolus, which are disrupted at considerably higher salt concentrations. Thus, the interactions between low-complexity RNA and the R/H-rich region of the ACM characteristic of step 1 in A-body biogenesis ([**Figure 2**](#f2){ref-type="fig"}) appear to be electrostatic in nature and are likely driven by complex coacervation, a charge-based form of liquid--liquid phase separation that has been observed in other cellular settings *in vivo* ([@B3]; [@B97]).

![The amyloid-converting motif (ACM). **(A)** The ACM is necessary and sufficient to target and immobilize proteins in amyloid bodies (A-bodies). It consists of a R/H-rich short cationic domain flanking a high fibrillation propensity domain (determined by Rosetta energy of less than −23 kcal/mol). **(B)** We propose that it is its bipartite nature that allows the ACM to traverse phase boundaries. Complex coacervation of short cationic domains and low-complexity rIGSRNA (liquid--liquid phase separation) concentrates fibrillation propensity domains to activate a liquid-to-solid phase transition to form A-bodies.](fgene-10-01179-g004){#f4}

Amyloidogenic Properties of the ACM Trigger Protein Immobilization {#s4_3}
------------------------------------------------------------------

In principle, A-bodies and Balbiani bodies should be composed of proteins that possess fibrillation propensity, i.e., increased likelihood of forming fibrils. Bioinformatic analysis of the consensus ACM revealed the hydrophobic LXV motifs make up a region of high fibrillation propensity, as predicted by a Rosetta energy score of less than −23 kcal/mol ([@B43]) ([**Figure 4A**](#f4){ref-type="fig"}). As a whole, the ACM bears a striking resemblance to that of the prototypical pathological β-amyloid, historically associated with Alzheimer's disease, in which a R/H-rich sequence is in close proximity to a region of high fibrillation propensity referred to in literature as the P3 fragment ([**Figure 4A**](#f4){ref-type="fig"}) ([@B32]). The ACM exhibits classic amyloidogenic properties previously observed for β-amyloid, namely, the cross-β X-ray diffraction pattern *in vivo* and the ability to form fibrils *in vitro* ([@B5]).

It has been proposed that the function of the initial liquid state is to locally concentrate proteins with fibrillation propensity that would otherwise be at levels below the critical threshold in the cell ([@B60]). Concentration-dependent activation of protein fibrillation has been well-documented *in vitro* ([@B33]; [@B60]). Indeed, markers of early or nascent A-bodies include ANS and A11 staining ([@B136]) that are typically used *in vitro* to indicate accumulating pre-amyloidogenic structures ([@B20]; [@B59]; [@B47]; [@B128]). In addition, photobleaching analyses revealed that the core of nucleolar foci contain immobile proteins. Nascent A-bodies expand by self-assembly, during which soluble proteins are added directly and autonomously to the growing amyloid structure ([**Figure 2**](#f2){ref-type="fig"}) ([@B136]).

The ACM Traverses Across Phase Boundaries to Confer A-Body Identity {#s4_4}
-------------------------------------------------------------------

As described above, low-complexity RNA sequences are important in conferring A-bodies their unique identity ([@B136]), adding to the list of architectural determinants, which includes sequence-specific RNA ([@B144]), mRNA secondary structure ([@B56]; [@B63]), and short unstructured RNA *in vitro* ([@B95]). The low-complexity rIGSRNA-mediated foci themselves appear immiscible from the three canonical compartments of the nucleolus ([@B38]; [@B136]), suggesting they exhibit distinct properties that may exclude mixing. Ultimately, it is the bipartite nature of the ACM that confers A-body identity and differentiates the ACM from other motifs. One possibility is that the R/H-rich "short cationic domain" mediates complex coacervation while the "fibrillation propensity domain" initiates amyloidogenesis to immobilize proteins in A-bodies ([@B5]; [@B136]) ([**Figure 4B**](#f4){ref-type="fig"}). In this model, proteins without a region of high fibrillation propensity are unlikely to be incorporated into A-bodies. In other words, while many proteins containing positively charged domains can form transient rIGSRNA-dependent nucleolar foci, only the ones that harbor high fibrillation propensity sequences will be found immobilized in A-bodies. The balance of positive to negative charge ratio, presence of polar and/or aromatic residues, and modifications ([@B10]; [@B90]) will affect how ACM engage in intermolecular interactions with other proteins and low-complexity RNA. Therefore, the ACM is versatile as it can physiologically transition proteins across phase boundaries.

Physiological Amyloids Promote Cell Dormancy {#s5}
============================================

Endogenous A-bodies have been found in primary cultures and cell lines exposed to various stimuli, the cores of human tumors, and subsets of cells in normal human and mouse tissues ([@B5]). So, while A-bodies share structural features with pathological amyloids, their ubiquitous and reversible nature is indicative of a physiological function. Pathway enrichment analysis determined that many of the proteins sequestered in A-bodies are involved in cell cycle regulation and DNA synthesis, such as CDK1, POLD1, and DNMT1 ([@B5]). By temporarily detaining key factors from their sites of activity into A-bodies, major molecular networks are disrupted, suppressing metabolic activity ([@B84]) and arresting proliferation/DNA synthesis ([@B5]). This is different from the quiescent state (G0) in the cell cycle where cells arrest proliferation but remain metabolically active. Therefore, the biological role of A-body formation is to promote cellular dormancy as an adaptive response to environmental stressors. These findings are consistent with reports that show Balbiani bodies ([@B18]) and fluid-to-solid transitions in yeast ([@B91]) promote dormancy, reinforcing the concept that cells utilize different states of matter to perform various biological functions ([**Table 2**](#T2){ref-type="table"}). The material properties of "solid-like" systems---non-dynamic, amyloid-like---result in loss of metabolic activity and promote cellular dormancy, while those of "liquid-like" systems---dynamic, fluid-like---concentrate and facilitate biochemical reactions.

A-Bodies as Targets for Therapeutic Discovery {#s6}
=============================================

Implications for Pathological Amyloids {#s6_1}
--------------------------------------

A-bodies that are physiologically produced remain confined within the nucleus and are considered non-toxic amyloids ([@B135]). How the nuclear environment alters the interaction properties of aggregation-prone proteins to prevent toxicity ([@B141]; [@B74]) compared to the cytoplasm is unclear. These results imply the cell tightly regulates the induction and degradation of low-complexity rIGSRNA within the nucleolus in response to stimuli. It is interesting that the pathological β-amyloid involved in Alzheimer's disease is an ACM and undergoes immobilization in A-bodies. Mutations that decrease the fibrillation potential of β-amyloid prevent its immobilization in A-bodies, providing a link between β-amyloid fibrillation and A-body biogenesis. It is tempting to speculate that disruptions of A-body biogenesis, for example by cell death, may provide the initial seeds for pathological amyloidogenesis. Whether aberrant production or localization of low-complexity RNA or exposure of A-bodies to the extracellular environment is involved in amyloid pathologies such as Alzheimer's and Huntington's diseases will be the subject of future studies.

Implications for Tumor Cell Dormancy and Metastasis {#s6_2}
---------------------------------------------------

Given the evidence that A-bodies are observed in the cores of tumors and promote cell dormancy ([@B5]), perhaps there is a link between A-body formation and tumor cell dormancy. This could allow cancer cells to adapt to the harsh hypoxic/acidotic conditions of the tumor microenvironment. Such a connection has pertinent implications for chemotherapeutic resistance and metastasis ([@B69]; [@B68]). With major metabolic pathways shut down and key drug targets stored away in A-bodies, a small population of dormant tumor cells may be resistant to treatment, survive for a prolonged period of time, and contribute to disease recurrence or metastasis upon their metabolic reactivation. Preventing cancer cells from forming A-bodies and going dormant or, more realistically, preventing cancer cells from reactivating may become a viable treatment option.

An interesting avenue of research that may offer a more effective cancer treatment strategy involves manipulating the proteins that evade capture into A-bodies. Interestingly, proteins that remain active to sustain basal metabolism and viability under stress tend to be devoid of fibrillation propensity domains and evade capture into A-bodies. These proteins would be more susceptible to manipulation and serve as better chemotherapeutic targets than proteins captured in A-bodies.

Discussion {#s7}
==========

Twenty years after its discovery, the study of nucleolar sequestration has led to important conceptual and mechanistical advances in our understanding of the role of membraneless bodies and how they are constructed. The ability of cells to reversibly cycle proteins from a mobile to immobile state in A-bodies represents an effective posttranslational mechanism to regulate molecular networks. In this review, we propose a stepwise working model of A-body biogenesis that highlights this process as a precisely choreographed multistep routine rather than a random aggregation of misfolded proteins. This also makes A-bodies unique from the liquid compartments that populate the cell. A-bodies are characterized by electron-dense fibers composed of an array of immobilized proteins that stain positive with various amyloidogenic dyes. Liquid condensates do not display amyloidogenic features and generally contain mobile proteins. Obviously, this raises the key question of why liquid condensates typically do not mature into bodies with amyloidogenic properties. One possibility is that the clusters of low-complexity rIGSRNA are able to recruit sufficient quantity of proteins by simple electrostatic interactions, thereby reaching the critical concentration threshold to trigger amyloidogenesis ([@B60]). This model is supported by the observation of electron-dense material early on in A-body biogenesis. The bipartite nature of the ACM, which can both electrostatically interact with low-complexity rIGSRNA and contains a high fibrillation propensity domain necessary for immobilization, may also explain the maturation of A-bodies. Perhaps the architectural determinants of RNA that seed various liquid bodies are too restrictive to certain binding partners to reach a concentration threshold required for amyloidogenesis. Additionally, there is evidence that suggests high nuclear RNA concentration acts as a buffer to prevent condensates from becoming amyloidogenic ([@B74]). Indeed, mutated proteins with increased propensity to form amyloids are preferentially formed in the cytoplasm, which has low RNA concentration. While this appears to be the case for cytoplasmic stress granules enriched in amyloidogenic mutant proteins, this likely does not explain A-body maturation as the nucleolus is highly enriched in rRNA. How A-bodies progress from liquid-like condensates to solid-like condensates is a major question in the field of condensate biology, which we are actively pursuing. We are also keen to explore other stimuli, particularly those that alter nucleolar architecture, that may promote the accumulation of rIGSRNA and the formation of A-bodies, including viral infection ([@B134]), inflammation, and diurnal cycles of metabolism. Diurnal oscillations in nucleolar size and abundance of nucleolar RNAs have been seen in mammalian systems ([@B124]; [@B2]), as well as an emerging connection between circadian disturbances and Alzheimer's disease ([@B93]). Despite most proteins having inherent fibrillation propensity, the dominant view remains that amyloids are inherently toxic, rather than a physiological fold exploited by cells to regulate various peptide functions. The challenge will be to decipher fundamental differences between A-bodies and other physiological or pathological membraneless compartments that could inform our understanding on how to prevent, detect, and treat amyloid-based diseases.
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